


SEQUENCE LISTING



<110> MIZUGUCHI, HIROYUKI
HAYAKAWA, TAKAO

<120> ADENOVIRUS VECTOR

<130> 081356/0163

<140> 09/845,160

<141> 2001-05-01

<150> JP 2001-131688

<151> 2001-04-27

<150> JP 2000-161577

<151> 2000-05-31

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide having
affinity with heparan sulfate.

<400> 1

Lys Lys Lys Lys Lys Lys

1

5

<210> 2

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide having
affinity with laminin receptor.

<400> 2

Thr Ser Gly Tyr Ile Gly Ser Arg Gly Tyr Ile Gly Ser Arg Gly Tyr

1

5

10

15

Ile Gly Ser Arg Ser Ser

20

<210> 3

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide having affinity with laminin receptor.

<400> 3

Thr Ser Ala Ala Ser Ile Lys Val Ala Val Ser Ile Lys Val Ala Val
1 5 10 15

<210> 4

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide having affinity with E-selectin.

<400> 4

Thr Arg Ser Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys Thr
1 5 10 15
Ser

<210> 5

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: RGD-4C peptide.

<400> 5

Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 6

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: NGR associating peptide.

<400> 6

Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys
1 5 10

<210> 7

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide 1.

<400> 7
 aacaggagac acaacttcga acatcgatcc aagtcgatac tctatgtcat tttcatggga 60
 ctgggtctggc cacaactaca t 81

<210> 8
 <211> 79
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Oligonucleotide 2.

<400> 8
 taatgtagtt gtggccagac cagtcccatg aaaatgacat agagtatgca cttggatcga 60
 tgttcgaagt tgtgtctcc 79

<210> 9
 <211> 10
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Oligonucleotide 3.

<400> 9
 cgттааттаа 10

<210> 10
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Oligonucleotide 4.

<220>
 <221> CDS
 <222> (3)..(29)

<400> 10
 cg aag tgt gac tgc cgc gga gac tgt ttc tg 31
 Lys Cys Asp Cys Arg Gly Asp Cys Phe Cys
 1 5 10

<210> 11
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Oligonucleotide 5.

<400> 11
 cgcagaaaca gtctccgcgg cagtcacact t 31

<210> 12
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Oligonucleotide 6.

<400> 12
 cggctgcaac ggccgctgcg tgagcggctg cgccggccgc tg 42

<210> 13
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Oligonucleotide 7.

<400> 13
 cgcagcggcc ggccgagccg ctcacgcagc ggccgttgca gc 42

<210> 14
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic peptide

<400> 14
 Lys Cys Asp Cys Arg Gly Asp Cys Phe Cys
 1 5 10